Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Shares Outstanding for 11 consecutive years, with $26.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 0.95% to $26.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 million through Dec 2025, up 0.95% year-over-year, with the annual reading at $26.0 million for FY2025, 0.95% up from the prior year.
  • Shares Outstanding for Q4 2025 was $26.0 million at Cartesian Therapeutics, roughly flat from $26.0 million in the prior quarter.
  • The five-year high for Shares Outstanding was $153.0 million in Q3 2022, with the low at $5.1 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $55.0 million, with a median of $26.0 million recorded in 2025.
  • The sharpest move saw Shares Outstanding plummeted 96.65% in 2023, then soared 377.39% in 2024.
  • Over 5 years, Shares Outstanding stood at $123.6 million in 2021, then plummeted by 95.87% to $5.1 million in 2022, then rose by 5.8% to $5.4 million in 2023, then soared by 377.39% to $25.8 million in 2024, then rose by 0.95% to $26.0 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $26.0 million, $26.0 million, and $26.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.